Clinicopathological characterization of tall cell carcinoma with reversed polarity of the breast: A case report and review of the litterature.

Int J Surg Case Rep

Immuno-cyto-histology Department, Salah Azeiz Institute, Tunis, Tunisia; Faculty of Medicine of Tunis, El Manar University, Tunis, Tunisia.

Published: November 2024

Introduction: Tall cell carcinoma of the breast with reverse polarity (TCCRP) is a recently described rare entity with low potential for malignancy which exhibits morphological features with tall cell variant of papillary thyroid carcinoma. Immunohistochemical and molecular studies help establish the diagnosis.

Case Report: We report the case of a 45-year-old woman with no significant medical or surgical history who presented with mastodynia. Physical examination was negative. Screening by bilateral mammography revealed a mass of the right breast which was classified as 4B. The mass was surgically excised. The pathological report concluded to a TCCRP of the breast with free margins. The tumor cells were negative for hormone receptors as well as for the Human Epidermal Growth Factor Receptor-2 (HER2neu). The patient underwent a sentinel lymph node dissection that was negative followed by loco-regional radiotherapy. Chemotherapy and endocrine therapy were not indicated for the patient. After 24 months of follow-up, no signs of loco-regional or distant recurrences have been identified.

Clinical Discussion: TCCRP is a rare entity that has been recently introduced in the WHO classification of breast cancer. It is usually a triple negative tumor, negative to TTF1 and thyroglobulin with low proliferation index, and a low potential for malignancy. Wide excision is the keystone of the treatment; however, chemotherapy and radiotherapy are still controversial due to lack of evidence.

Conclusion: TCCRP is a rare entity, which carries an excellent prognosis. A proper diagnosis is essential to conduct the best treatment next to a careful follow-up due to the ambiguous natural history of this rare entity.

Papers That Have Been Previously Published As Meeting Abstracts: None.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539130PMC
http://dx.doi.org/10.1016/j.ijscr.2024.110444DOI Listing

Publication Analysis

Top Keywords

tall cell
12
rare entity
12
cell carcinoma
8
low potential
8
potential malignancy
8
tccrp rare
8
breast
5
negative
5
clinicopathological characterization
4
characterization tall
4

Similar Publications

Chromatin hubs drive key regulatory networks in leukemia.

Mol Cell

January 2025

Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA. Electronic address:

In this issue of Molecular Cell, Gambi, Boccalatte, Hernaez, et al. apply multiomics followed by genetic engineering to define then characterize epigenetic hubs that regulate processes crucial for T-ALL and use this insight to offer new avenues for therapeutic targeting.

View Article and Find Full Text PDF

Neo-enhancers in T-cell acute lymphoblastic Leukaemia (T-ALL) and beyond.

Int J Cancer

January 2025

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

T-cell acute lymphoblastic leukaemia (T-ALL) is a rare aggressive haematological malignancy characterised by the clonal expansion of immature T-cell precursors. It accounts for 15% of paediatric and 25% of adult ALL. T-ALL is associated with the overexpression of major transcription factors (TLX1/3, TAL1, HOXA) that drive specific transcriptional programmes and constitute the molecular classifying subgroups of T-ALL.

View Article and Find Full Text PDF

Phospholipids are the most abundant component in lipid membranes and are essential for the structural and functional integrity of the cell. In eukaryotic cells, phospholipids are primarily synthesized de novo through the Kennedy pathway that involves multiple enzymatic processes. The terminal reaction is mediated by a group of cytidine-5'-diphosphate (CDP)-choline /CDP-ethanolamine-phosphotransferases (CPT/EPT) that use 1,2-diacylglycerol (DAG) and CDP-choline or CDP-ethanolamine to produce phosphatidylcholine (PC) or phosphatidylethanolamine (PE) that are the main phospholipids in eukaryotic cells.

View Article and Find Full Text PDF

Approach to the Patient with Thyroid Cancer: Selection and Management of Candidates for Lobectomy.

J Clin Endocrinol Metab

January 2025

Department of Otolaryngology-Head and Neck Surgery, Beilinson Hospital, Rabin Medical Center.

Thyroid lobectomy has gained increasing popularity over the past decade as a treatment for differentiated thyroid cancer (DTC), largely due to a rise in the diagnosis of low-risk cancers and evidence showing no benefit from radioiodine in low-risk disease. Multiple studies have confirmed lobectomy as an effective and safe option. Its advantages over total thyroidectomy include lower complication rates and a reduced need for lifelong levothyroxine (LT4) therapy.

View Article and Find Full Text PDF

[The Factors Related to Treatment Failure in Children with Acute Lymphoblastic leukemia--Analysis of Multi-Center Data from Real World in Fujian Province].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

December 2024

Department of Pediatric Hematology, Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fujian Provincial Key Laboratory, Fuzhou 350001, Fujian Province, China.

Objective: To analyze the related factors of treatment failure in children with acute lymphoblastic leukemia (ALL) in real-world.

Methods: The clinical data of 1414 newly diagnosed children with ALL admitted to five hospital in Fujian province from April 2011 to December 2020 were retrospectively analyzed. Treatment failure was defined as relapse, non-relapse death, and secondary tumor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!